This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.
Participant must be considered likely incurable given a standard of care. This is inclusive of participants in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but not curative options for care.
Participant must have a life expectancy greater than 3 months
Participant must have an ECOG performance status 0-2
Participant and primary Oncologist are willing to consider the therapeutic strategies recommended by the ETB
None